Various cancer biomarkers associated with ovarian cancers have been considered for the design of tumor-targeting agents, including the folate receptor, VEGF, EGFR, HER2, epCAM, PSMA, and αvβ3 integrin [3,5]. This evidence concerns the gene ERBB2 and cancer.